Natco Pharma approves ₹1,300 crore rights issue, revises demerger scheme
Natco Pharma approved a rights issue of up to ₹1,300 crore via equity shares of face value ₹2. A Fund-Raising Committee was formed. The company will also revise its demerger scheme with Natco Crop Health Sciences Limited to accommodate changes from the rights issue.
The rights issue of ₹1,300 crore is a substantial amount and will significantly impact the company's capital structure and shareholding pattern. The consequential changes to the demerger scheme also indicate a significant corporate action.
The company is undertaking a significant equity fundraising through a rights issue, which is generally viewed positively as it strengthens the company's financial position and provides capital for growth. The revision of the demerger scheme to align with the rights issue indicates strategic planning.
Natco Pharma Limited's Board of Directors, in a meeting held on September 9, 2026, has approved the issuance of fully paid-up equity shares worth up to ₹1,300 crore through a rights issue to eligible shareholders. The face value of these equity shares is ₹2 each.
The board also approved the formation of a Fund-Raising Committee, comprising Sri V.C. Nannapaneni (Chairman), Sri Rajeev Nannapaneni (Member), and Sri P.S.R.K. Prasad (Member), to oversee the rights issue.
Furthermore, the company provided an update on its Scheme of Arrangement (Demerger) between Natco Pharma Limited and Natco Crop Health Sciences Limited. While the scheme has received observation letters from both stock exchanges, the company has not yet filed it with the National Company Law Tribunal. The board decided to make necessary consequential changes to the Scheme post-completion of the rights issue to maintain the proposed share swap ratio. Revised filings will be made with the stock exchanges after the rights issue is completed.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.